Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intra-arterial, Oral, Intravenous
01
Overview
Irinotecan liposome + 5-FU/LV + lenvatinib + tislelizumab is a multi-agent combination regimen under clinical investigation for the first-line treatment of unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma (ICC). The regimen combines regional and systemic therapies: hepatic arterial infusion chemotherapy (HAIC) using liposomal irinotecan (a topoisomerase I inhibitor), 5-fluorouracil (an antimetabolite), and leucovorin (a biochemical modulator); oral lenvatinib (a multi-target receptor tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR, RET, and KIT); and tislelizumab (a PD-1 immune checkpoint inhibitor). This approach aims to maximize local tumor control in the liver while providing systemic anti-angiogenic and immunotherapeutic effects. The regimen is currently being evaluated in a Phase 2 trial (NCT07646717) sponsored by Tianjin Medical University Cancer Institute and Hospital.
- Other names
- LPHAICHAIC + Lenvatinib + TislelizumabLPHAIC for ICC
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)TOP1 (DNA Topoisomerase I)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + fluorouracil + leucovorin + lenvatinib + tislelizumab.